Kai-wen Y. Huang
No. 7 Chung Shan S. Rd
TPQ 10002, Taiwan
TPQ 10002, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.
Journal: Frontiers in medicine
Published: February 18, 2026
GalNAc-conjugated siRNA targeting C/EBPβ reverses metabolic dysfunction and restores liver homeostasis in a murine MASLD model.
Journal: Molecular therapy. Nucleic acids
Published: October 23, 2025
Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation.
Journal: Hepatology international
Published: September 30, 2025
Short-term and patient-reported outcomes of laser hemorrhoidoplasty plus excisional hemorrhoidectomy for the treatment of grade IV hemorrhoid.
Journal: Scientific reports
Published: June 05, 2025
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.
Journal: Liver cancer
Published: October 27, 2024
Staging Paradox and recurrence pattern among stage IIB, IIC, and IIIA Colon cancers: a retrospective cohort study.
Journal: International journal of colorectal disease
Published: October 06, 2024
Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis: A Systematic Review and Meta-Analysis.
Journal: Journal of clinical medicine
Published: June 03, 2024
Savoring Belief, Resilience, and Meaning in Life as Pathways to Happiness: A Sequential Mediation Analysis among Taiwanese University Students.
Journal: Behavioral sciences (Basel, Switzerland)
Published: March 13, 2024
Lactobacillus rhamnosus Ameliorates Dyslipidemia and Liver Steatosis in a Rat Model Fed High-Fat Diet.
Journal: Gastroenterology research and practice
Published: February 22, 2024
Potential of Using qFibrosis Analysis to Predict Recurrent and Survival Outcome of Patients with Hepatocellular Carcinoma after Hepatic Resection.
Journal: Oncology
Published: January 08, 2024
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Journal: Cell reports. Medicine
Published: November 16, 2023
Last Updated: 09/26/2026